The evolving role of immunotherapy in prostate cancer

Annals of Oncology

Volumn 23, Issue SUPPL.8, 2012, Pages

  Gerritsen, W R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Castration resistant prostate cancer; GVAX; Immunotherapy; Sipuleucel T; T cell modulation; Vaccines

Indexed keywords

CANCER VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; PLACEBO; SIPULEUCEL T;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONFERENCE PAPER; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOMODULATION; INGUINAL PAIN; INJECTION SITE REACTION; LUNG ALVEOLITIS; MONOTHERAPY; MYALGIA; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; MALE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 84865533895     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds259     Document Type: Conference Paper

References (38)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Altekruse SF, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. http://seer.cancer.gov/.
3. United Nations DoEaSAPD. World Population Ageing: 1950-2050. United Nations New York, 2002; Available at: http://www.un.org/esa/population/publications/worldageing19502050/.
4. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10: 580-593.
5. Horwich A, Parker C, Bangma C et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v129-v133.
6. NCCN. National comprehensive cancer network: clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (2010).
7. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
8. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
9. Tannock IF, de WR, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
10. Gannon PO, Poisson AO, Delvoye N et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348: 9-17.
11. Palena C, Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol 2010; 2010: 380697.
12. Sierro SR, Donda A, Perret R et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011; 41: 2217-2228.
13. Higano CS, Small EJ, Schellhammer P et al. Sipuleucel-T. Nat Rev Drug Discov 2010; 9: 513-514.
14. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
15. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105.
16. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011; 17: 3884-3891.
17. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
18. Kantoff P, Higano C, Berger E et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol (Genitourinary Cancers Symposium) 2010; Abstr 8.
19. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388-1397.
20. Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
21. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol 2005; 32: 549-555.
22. May KF, Jr, Gulley JL, Drake CG et al. Prostate cancer immunotherapy. Clin Cancer Res 2011; 17: 5233-5238.
23. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 663-674.
24. Madan RA, Gulley JL, Dahut WL et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design. J Clin Oncol 2008; 26(15 Suppl): 133s, Abstr 3005.
25. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283.
26. Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-1815.
27. Slovin SF, Beer TM, Higano CS et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009; 27(15 Suppl): 268s, Abstr 5138.
28. Small E, Higano C, Tchekmedyian N et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol 2006; 24(18 Suppl): 243s, Abstr 4609.
29. Kaehler KC, Piel S, Livingstone E et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-498.
30. Beer TM, Logothetis C, Sharma P et al. Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). J Clin Oncol 2011; 29(15 Suppl): 27s, Abstr TPS182.
31. Drake CG, Scher HI, Gerritsen WR et al. A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). J Clin Oncol 2011; 29(15 Suppl): 27s, Abstr TPS181.
32. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010; 16: 304-310.
33. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17: 6958-6962.
34. van EA, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-366.
35. Gerritsen W, van den Eertwegh AJ, de Gruijl T et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol 2008; 26(15 Suppl): 285s, Abstr 5146.
36. van den Eertwegh AJ, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factortransduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012 [Epub ahead of print].
37. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237.
38. DeFrancesco L. Landmark approval for dendreon's cancer vaccine. Nat Biotechnol 2010; 28(6): 531-532.